We are live on ! Find out more
BLFS icon

BioLife Solutions

82 hedge funds and large institutions have $244M invested in BioLife Solutions in 2020 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 31 increasing their positions, 18 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

110% more capital invested

Capital invested by funds: $116M → $244M (+$128M)

89% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 9

72% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 18

33% more funds holding in top 10

Funds holding in top 10: 34 (+1)

9% more funds holding

Funds holding: 7582 (+7)

1.45% less ownership

Funds ownership: 59.01%57.55% (-1.5%)

Holders
82
Holders Change
+7
Holders Change %
+9.33%
% of All Funds
1.68%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.08%
New
17
Increased
31
Reduced
18
Closed
9
Calls
$265K
Puts
Net Calls
+$265K
Net Calls Change
+$449K

BLFS Hedge Fund Activity: Q2 2020 in Review

82 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in BioLife Solutions (BLFS) for Q2 2020, worth a combined $244M — up 110% from $116M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new BLFS positions and 9 closed out — a net gain of 8 holders — while 31 added to existing stakes and 18 trimmed.

The largest buyer was Casdin Capital, adding an estimated $32.8M. The largest seller was Penn Capital Management, exiting entirely with an estimated $3.07M sold.

  • 82 institutional investors held BioLife Solutions (BLFS) as of Q2 2020, up from 75 in Q1 2020.
  • Funds reported $244M of BioLife Solutions stock for Q2 2020, up 110% quarter-over-quarter.
  • 17 funds opened new BioLife Solutions positions in Q2 2020 and 9 closed out, a net change of +8 holders.
  • The largest BioLife Solutions buyer in Q2 2020 was Casdin Capital, an estimated $32.8M added.
  • The largest BioLife Solutions seller in Q2 2020 was Penn Capital Management, an estimated $3.07M sold.

Based on aggregated 13F filings for Q2 2020.